Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
CME Credit Available: Maximum of 7.0 AMA PRA Category 1 Credits™
Release Date: May 13, 2008
Expiration: May 13, 2009
This activity consists of a live audio and visual broadcast live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Describe the state of the HIV epidemic in Washington, DC, and discuss the impact on clinical care
- Outline the pathogenesis of metabolic complications of HIV and its therapies (eg, diabetes mellitus and lipodystrophy)
- Design antiretroviral strategies that consider data on:
- The management of complicated failure, use of resistance testing, and the role of newly approved drugs in antiretroviral regimens
- The status of investigational antiretroviral drugs
- Renal disease as a complication of HIV and its therapies
- Discuss the latest treatment issues in opportunistic infections and immune reconstitution inflmmatory syndrome
- Formulate appropriate strategies for managing mental health issues in HIV-infected patients
- Describe the incidence, diagnosis, and management of hepatitis C virus coinfection with HIV, including the status of investigational agents
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of
7.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Intended Audience
This online CME activity is designed for advanced clinicians who are actively involved in HIV/AIDS care. Specifically, this activity has been designed for physicians, physician assistants, nurse practictioners, and nurses who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
Course Faculty
Chairs
Henry Masur, MD
Clinical Professor of Medicine
George Washington University School of Medicine
Washington, District of Columbia, and
Bethesda, Maryland
Michael S. Saag, MD
Volunteer Director
International AIDS Society–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Division of Infectious Diseases and
The William C. Gorgas Center for
Geographic Medicine
Director, Center for AIDS Research
University of Alabama at Birmingham
Speakers
Richard T. D’Aquila, MD
Addison B. Scoville Jr Professor of Medicine
Director, Division of Infectious Diseases
Vanderbilt University School of Medicine
Nashville, Tennessee
Steven K. Grinspoon, MD
Professor of Medicine
Harvard Medical School
Director, MGH Program in Nutritional Metabolism
Massachusetts General Hospital
Boston, Massachusetts
Shannon L. Hader, MD, MPH
Senior Deputy Director
HIV/AIDS Administration
Department of Health
District of Columbia
Fred R. Sattler, MD
Professor of Medicine and Biokinesiology
Division of Infectious Diseases
University of Southern California School of Medicine
Los Angeles, California
Lynda A. Szczech, MD
Associate Professor
Duke University Medical Center
Durham, North Carolina
David L. Thomas, MD, MPH
Professor of Medicine
Director, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland
Glenn J. Treisman, MD, PhD
Associate Professor
Director, AIDS Psychiatry Services
Johns Hopkins Medical Institutions
Baltimore, Maryland
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research grants awarded to University of California, San Diego from Gilead Sciences. Dr Benson served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Merck, and Pfizer, and chaired Data and Safety Monitoring Boards for Johnson & Johnson Research, Ltd. (Australia) and Achillion. (Updated 05/02/08)
Judith S. Currier, MD
Dr Currier (3/12/07-2/15/08) received research grants to UCLA from Tibotec, Merck, GlaxoSmithKline and Theratechnologies and served as a consultant or received honoraria from Bristol-Myers Squibb, Pfizer, Merck, and Tibotec. In addition she serves on a data safety monitoring board for Koronnis and Achillion Pharmaceuticals. (Updated 02/15/08)
Carlos del Rio, MD
Dr del Rio (3/12/07–2/15/08) received research grants to Emory University from Merck, GlaxoSmithKline, Pfizer, the CDC and the NIH. He served as a consultant or received honoraria from Merck, Trinity Biotech and BMS. (Updated 02/15/08)
Joel E. Gallant, MD, MPH
Dr Gallant received research grants awarded to Johns Hopkins University School of Medicine from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, RAPID Pharmaceuticals, Schering Plough, Tibotec, and Vertex. He is a member of Data Safety and Monitoring Boards for Abbott, Gilead, and Koronis. (Updated 02/15/08)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants to Cornell University from Panacos, Pfizer, Schering, and Tibotec. He served as an ad-hoc scientific advisor or consultant to Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Schering, Trimeris, Virco, and Virostatics. He also serves as Chair of a DSMB for Koronis. (Updated 03/24/08)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 05/02/08)
Douglas D. Richman, MD
Dr Richman served as a consultant to Anadys, Biota, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Idinex, Koronis, Merck, Monogram, Pfizer, Roche, and Tobira. (Updated 02/19/08)
Michael S. Saag, MD
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 05/02/08)
Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram, Pfizer, TaiMed, Tibotec, and Vertex. He had stock options for Achillion and Monogram. (Updated 05/02/08)
Paul A. Volberding, MD
Dr Volberding, during the period from 1/1/07 through 1/1/08, served on scientific advisory boards for Bristol-Myers Squibb, Gilead, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering for an ongoing clinical trial. He received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 03/05/08)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr D’Aquila received research support and honoraria from or served as a consultant to and on a scientific advisory boards of Abbott, Ambergen, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Merck, Monogram Bioscience, Schering, Tibotec, and Virco. (Updated 05/02/08)
Dr Grinspoon received research support from Bristol-Myers and GlaxoSmithKline and served as a consultant to Theratechnologies. (Updated 05/02/08)
Dr Hader had no relevant financial affiliations to disclose. (Updated 05/02/08)
Dr Masur had no relevant financial affiliations to disclose. (Updated 05/02/08)
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 05/02/08)
Dr Sattler had no relevant financial affiliations to disclose. (Updated 05/02/08)
Dr Szczech received research support and honoraria from or served as a consultant to Gilead and GlaxoSmithKline. (Updated 05/02/08)
Dr Thomas served as a consultant to Merck. (Updated 05/02/08)
Dr Treisman served on the speakers’ bureaus for Abbott and Boehringer Ingelheim. (Updated 05/02/08)
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live Webcast is provided by the National Resource Center of the AIDS Education and Training Centers through the Health Resources and Services Administration.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Merck & Co., Inc.
Pfizer Global Pharmaceuticals
Generous Grants from:
GlaxoSmithKline
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2008@iasusa.org
